The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) is the only research consortium dedicated to evaluating the real-world safety and effectiveness of biologics, including biosimilars.
BBCIC is a non-profit research consortium that monitors the safety and effectiveness of biosimilars and novel biologics and provides the assurance needed to determine which medications deliver the best health outcomes.
AMCP established BBCIC in 2015 to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars, and other related products. The BBCIC’s mission is to provide research services that:
- Address important questions about the use, impact, safety, and clinical effectiveness of biologics including biosimilars on human health
- Increase the rigor and credibility of real-world evidence
- Provide access to a large population for epidemiologic studies and health services research
- Improve the efficiency and cost-effectiveness of post-marketed observational studies
- Develop standard approaches to common data needs and address gaps in tools and methods
Harvard Pilgrim Health Care Institute provides coordination and analytical support for BBCIC, with Jeffrey Brown, PhD serving as project lead. Other key team members include Sarah Malek, MPPA; James Marshall, MPH; Aaron Mendelsohn, PhD, MPH: and Young Hee Nam, PhD.
- Mendelsohn AB, Marshall J, McDermott CL, Pawloski PA, Brown JS, Lockhart CM. Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product. Drugs – Real World Outcomes. Online First. doi:https://doi.org/10.1007/s40801-021-00228-9.
- He M, Ortiz AJS, Marshall J, Mendelsohn AB, Curtis JR, Barr CE, Lockhart CM, Kim SC. Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. Pharmacoepidemiology and Drug Safety. 2020;29(7):770-777. doi:https://doi.org/10.1002/pds.4933.
- Zhang J, Haynes K, Mendelsohn AB, Marshall J, Barr CE, McDermott C, Brown J, Kline A, Kenney J, King KJ, Holmes C, Yeung K, Barron J, Yun H, Lockhart CM. Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims. Pharmacoepidemiology and Drug Safety. 2020;29(7):778-785. doi:https://doi.org/10.1002/pds.4934.
- Zhang J, Sridhar G, Barr CE, Eichelberger B, Lockhart CM, Marshall J, Clewell J, Accortt NA, Curtis JR, Holmes C, McMahill-Walraven CN, Brown JS, Haynes K. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance. JMCP. 2020;26(4):417-490. doi:10.18553/jmcp.2020.26.4.417.
- Mendelsohn AB, Nam YH, Marshall J, McDermott CL, Kochar B, Kappelman MD, Brown JS, Lockhart CM. Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population. Pharmacology Research & Perspectives. 2021;9(1):e00708. doi:https://doi.org/10.1002/prp2.708.